Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BECTON DICKINSON & COBDX · Entity 2498 | Director | January 27, 2026 | January 29, 2026 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BECTON DICKINSON & CO
Report date January 27, 2026 · Filed January 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,391 |
Reported balance
After 2026-01-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-27 · Grant · Acquired 1,098 · Balance 3,391 F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2: Includes units acquired through dividend investment since the last report filed by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan.
F2: Includes units acquired through dividend investment since the last report filed by the reporting person.
Structure Therapeutics Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-06-16 | Direct | 39,453 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 39,453 · Balance 39,453 F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs").
F2: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting,
F3: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:00 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 39,453 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001962413-26-000002 · form4-06182026_050609.xml · derivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,453 Underlying: Ordinary Shares · 39,453 shares Expires 2036-06-16 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 17, 2026, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2027 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 14:44 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 1,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-003999 · wk-form4_1769697838.xml · nonDerivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,391 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend investment since the last report filed by the reporting person. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 21:45 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 51,804 | $0.00 Strike: $7.37 | $0.00 |
DisclosureSEC source: 0001415889-25-018216 · form4-06252025_050607.xml · derivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,804 Underlying: Ordinary Shares · 51,804 shares Expires 2035-06-22 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting, F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| January 28, 2025 Filed Jan 30, 2025 20:52 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 930 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001286 · form4.xml · nonDerivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,270 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 20:15 UTC | Structure Therapeutics Inc. GPCR · Entity 1222 | GrantShare Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $13.32 | $0.00 |
DisclosureSEC source: 0001415889-24-018327 · form4-06272024_040607.xml · derivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Ordinary Shares · 37,500 shares Expires 2034-06-24 F1 · derivative.exercise_price: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). F2 · derivative.exercise_date: The shares vest in equal monthly installments over the 12 months following June 25, 2024. F3 · derivative.underlying_shares: The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer. Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 21:21 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001317 · form4.xml · nonDerivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,323 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. F2 · balance_after: Includes units acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document |
| July 24, 2023 Filed Jul 24, 2023 21:08 UTC | BECTON DICKINSON & CO BDX · Entity 2498 | GrantCommon Stock | 419 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-015249 · form4.xml · nonDerivative · entry 1 Waldstreicher Joanne · CIK 0001962413 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419 F1 · shares: Represents restricted stock units awarded under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.